Proofpoint's Varonis deal: $423 million is the debt-failure backstop

Proofpoint's $49.75 a share values Varonis at 8 times SaaS recurring revenue, while free cash flow is thin. The $423.3 million reverse fee and the debt behind it set the deal's risk.

Proofpoint has agreed to buy Varonis for $49.75 a share in cash. The release values the deal at about $6.3bn. Proofpoint is a portfolio company of Thoma Bravo, the private equity firm. The contract matters more than the headline price because it decides who carries the risk if the debt fails.

The important number sits in Item 1.01 of the 8-K. Proofpoint would owe Varonis a reverse termination fee of $423.3m. That is the penalty payable to the target if the buyer fails to close when required. It is exactly twice the $211.7m Varonis would owe Proofpoint.

Twice the break fee is the sponsor norm. Thoma Bravo's own 2021 purchase of Proofpoint carried a $676.4m reverse fee against a $368.9m company fee. That was a ratio of 1.8, according to the 2021 proxy statement. That deal also had a go-shop window for finding rival bidders. A rival found in that window carried a lower company fee of $122.98m.

This contract is specific about the route to the money. The 8-K says the buyer's obligations are not subject to a financing condition. Proofpoint cannot walk because its lenders do. Varonis can force the equity commitment only if the debt "has been or will be funded at Closing".

If the debt does not arrive, the reverse fee is what Varonis is left with. It equals 6.7% of the deal, against 3.4% for the break fee. It is payable if Proofpoint fails to close when required, and if Varonis terminates over an uncured Proofpoint breach, among other cases.

The lenders' commitment letters decide whether Varonis gets a closing or a cheque. The preliminary proxy statement will be the first place to read their terms. The press release says the financing rests on committed equity from Thoma Bravo, debt commitments, and an investment from Ontario Teachers' Pension Plan.

The deal needs a Varonis shareholder vote. It also needs the US antitrust waiting period to expire and specified foreign clearances by 15 July 2027, extendable by three months. Closing is expected in the first half of 2027. A material adverse effect clause lets a buyer exit after major unexpected harm to the target.

The release values Varonis at 8.4 times last-twelve-months revenue, calculated on enterprise value. Enterprise value is equity price plus debt, less cash. Revenue for 2025 was $623.5m per the 10-K. Adding the first half of 2026 and removing the first half of 2025 gives $688.1m. That implies enterprise value of about $5.78bn.

SaaS annual recurring revenue, or ARR, was $726.0m at 30 June, up 52% year on year per the 10-Q. Against that figure, the same enterprise value is about 8.0 times. The deal price fixes enterprise value, so any rise in ARR can only lower that multiple.

SaaS was 65% of revenue in the first quarter of 2025 and 95% in the second quarter of 2026. Quarterly revenue of $180.0m annualises to $720m, within 1% of recurring revenue. The gap is closing because Varonis has announced the end of life of its self-hosted business on 31 December 2026. After that date, a revenue multiple and an ARR multiple are the same multiple.

The premium looks large against the 22 June close of $32.71, at 52%. It is only 17% over the $42.35 close on 1 September. Deal talk had already lifted the shares by then.

The cash flow behind that multiple is thinner than the revenue multiple suggests. The release quotes 53 times last-twelve-months free cash flow, measured on market capitalisation. It defines free cash flow as operating cash flow less purchases of property and equipment and capitalised internal-use software. On the 10-K and 10-Q figures, that is $118.3m.

Share-based compensation, the stock paid to staff instead of cash, was $132.5m over the same period. That is more than the free cash flow to which the 53 times is applied. Varonis recorded an operating loss of $40.6m in the second quarter alone.

Part of that thin cash flow is the cost of a transition. Moving multi-year self-hosted licences to SaaS annual billing depresses cash, and deferred revenue fell $6.7m in the first half. A sponsor can cut the cost base after closing, and the price assumes it does. At 8 times recurring revenue with nothing left after share pay, Thoma Bravo is paying today for margin it has not yet taken out. That makes the reverse fee and the debt behind it the cost of being wrong.

The sale process gives the seller less protection than the fee suggests. Chief executive Faitelson described a committee of independent directors that ran "extensive outreach to a range of potential strategic and financial buyers". The 8-K describes a customary no-shop clause that bars Varonis from seeking other bidders. A rival must outbid $49.75 and fund the $211.7m Varonis would owe Proofpoint.

Faitelson holds about 0.67% of the shares and has signed a support agreement. At that size, his stake is too small to carry the vote. The preliminary proxy statement, which Varonis must file before holders vote, will carry a Background of the Merger section showing who else bid.

The first test comes on 3 November, when Varonis reports third-quarter results without an earnings call. The price is fixed, so only growth can change the multiple. If SaaS ARR growth stays near June's 52%, the 8 times shrinks as ARR rises. If it slows sharply, Thoma Bravo is paying 8 times for a slower business. The 31 December shutdown then ends the supply of self-hosted customers left to convert.